Connect with us

Hi, what are you looking for?

POZ

New long-acting HIV treatment expands options for people troubled by taking daily pills, virus is resistant to common HIV drugs

A new approach replaces rilpivirine with lenacapavir, a long-acting drug that attacks HIV in a different way.

A new long-acting HIV treatment could expand options for people who have trouble taking daily pills and whose virus is resistant to some commonly used HIV drugs.

This is according to a study that was published in JAMA Network Open.

Unlike daily HIV pills, long-acting treatments can be given weeks or months apart, which can make it easier for people who struggle to take medication every day. The only approved long-acting combination pairs cabotegravir with rilpivirine. But HIV can develop resistance to rilpivirine and related drugs, limiting its use for some people. Moreover, rilpivirine is not available in low- and middle-income countries.

“Clinicians are already starting to use these two drugs together, and until now we’ve had very little evidence to guide us,” said Monica Gandhi, MD, MPH, senior author of the paper and a UCSF professor of Medicine. “This is the largest group studied on this combination, and we think these findings could help providers have more confidence using it.”

Researchers at UCSF’s Ward 86 HIV Clinic studied 46 people who received long-acting lenacapavir and cabotegravir. Nearly three-quarters had the type of drug resistance that can limit use of the approved combination, and more than half had detectable HIV when they started treatment.

All participants who started with detectable HIV brought the virus under control within 13 weeks, while those who already had it under control stayed that way. After a median follow-up of nearly two years, all participants continued to have undetectable HIV viral loads, the goal of HIV therapy.

The combination is not yet approved as an HIV treatment, and the study did not compare it directly with other treatments. Two clinical trials are planned to study the approach more closely.

But the findings could influence care before those trials are completed. Lenacapavir and cabotegravir are becoming more widely available around the world, including through agreements that allow generic versions in many lower-income countries.

Advertisement. Scroll to continue reading.
Advertisement
Advertisement

Like Us On Facebook

YOU MAY ALSO LIKE

From the Editor

Notice one thing: Walang nananawagan para bumaba na sa puwesto si Marcos for the good of the country. And that’s why malakas ang loob...

POZ

Aging markedly increases renal stem-cell susceptibility to TFV-induced telomere–mitochondrial dysfunction, oxidative stress, senescence, apoptosis, and functional injury, while highlighting the 3D silk matrix model...

POZ

The US Food and Drug Administration gave its seal of approval to a generic version of injectable lenacapavir, the drug that can protect from...

POZ

Tuberculosis (TB) is responsible for about a quarter of all AIDS deaths. In 2024, it was also the leading cause of death among people...

Advertisement